In a new study published in the scientific journal Oncotarget researchers from Uppsala University show that a therapeutic vaccine directed against tumor vessels can reduce tumor burden and suppress formation of spontaneous lung metastases in a mouse model for metastatic breast cancer.
The target molecule of the immunization strategy is the extra domain-A (ED-A) of fibronectin, a protein domain which is highly selective for the tumor vasculature in the adult.
“The vaccination approach we have employed is not prophylactic but therapeutic, meaning that immunity was induced after the onset of tumorigenesis - a scenario that resembles the clinical conditions much more closely than prophylactic immunization studies, says Anna-Karin Olsson, researcher at the Department of Medical Biochemistry and Microbiology at Uppsala University”, who has led the study.
The therapeutic effect was significant, despite the aggressive nature of the tumor model. Moreover, the vaccine induced an 80 percent reduction metastasis, which is an important finding considering that a majority of all deaths by cancer are caused by cancer that has spread in the body.
A major advantage of the approach is that the target molecule ED-A is present in the majority of solid tumors. Vaccination against ED-A could therefore provide a treatment strategy with broad applications in cancer therapy. Furthermore, the researchers show that their strategy for immunization against a self-molecule is highly efficient and can be achieved with an adjuvant (immunostimulatory compound included in vaccines) that is acceptable for use in the clinic. The lack of potent, but at the same time non-toxic and biodegradable adjuvants has been a major limitation in the development of therapeutic vaccines.
Another important aspect is that therapeutic vaccination (endogenous production of the target antibodies) can provide a cost-efficient alternative to administration of large amounts of monoclonal antibodies, currently in clinical use for cancer and other diseases. The high costs associated with monoclonal antibody-based therapies puts a significant strain on the health-care economy, which may limit accessibility for patients.
“In conclusion, we believe therapeutic vaccination could provide a new, potent and cost-efficient treatment strategy for solid tumors and metastasizing cancer”, says Anna-Karin Olsson.
For more information, please contact Anna-Karin Olsson, tel: +46-18 471 4399 or +46-730 573013 or e-mail: Anna-Karin.Olsson@imbim.uu.se
“Therapeutic vaccination against fibronectin ED-A attenuates progression of metastatic breast cancer”, Julia Femel, Elisabeth JM Huijbers, Falk Saupe, Jessica Cedervall, Lei Zhang, Pernilla Roswall, Erik Larsson, Helena Olofsson, Kristian Pietras, Anna Dimberg, Lars Hellman and Anna-Karin Olsson
Anna-Karin Olsson | EurekAlert!
Rutgers-led innovation could spur faster, cheaper, nano-based manufacturing
14.02.2018 | Rutgers University
New study from the University of Halle: How climate change alters plant growth
12.01.2018 | Martin-Luther-Universität Halle-Wittenberg
In just a few weeks from now, the Chinese space station Tiangong-1 will re-enter the Earth's atmosphere where it will to a large extent burn up. It is possible that some debris will reach the Earth's surface. Tiangong-1 is orbiting the Earth uncontrolled at a speed of approx. 29,000 km/h.Currently the prognosis relating to the time of impact currently lies within a window of several days. The scientists at Fraunhofer FHR have already been monitoring Tiangong-1 for a number of weeks with their TIRA system, one of the most powerful space observation radars in the world, with a view to supporting the German Space Situational Awareness Center and the ESA with their re-entry forecasts.
Following the loss of radio contact with Tiangong-1 in 2016 and due to the low orbital height, it is now inevitable that the Chinese space station will...
Fraunhofer Institute for Organic Electronics, Electron Beam and Plasma Technology FEP, provider of research and development services for OLED lighting solutions, announces the founding of the “OLED Licht Forum” and presents latest OLED design and lighting solutions during light+building, from March 18th – 23rd, 2018 in Frankfurt a.M./Germany, at booth no. F91 in Hall 4.0.
They are united in their passion for OLED (organic light emitting diodes) lighting with all of its unique facets and application possibilities. Thus experts in...
A new scenario seeking to explain how Mars' putative oceans came and went over the last 4 billion years implies that the oceans formed several hundred million...
For the first time, an interdisciplinary team from the University of Basel has succeeded in integrating artificial organelles into the cells of live zebrafish embryos. This innovative approach using artificial organelles as cellular implants offers new potential in treating a range of diseases, as the authors report in an article published in Nature Communications.
In the cells of higher organisms, organelles such as the nucleus or mitochondria perform a range of complex functions necessary for life. In the networks of...
Animal photoreceptors capture light with photopigments. Researchers from the University of Göttingen have now discovered that these photopigments fulfill an...
19.03.2018 | Event News
16.03.2018 | Event News
13.03.2018 | Event News
21.03.2018 | Physics and Astronomy
21.03.2018 | Materials Sciences
21.03.2018 | Life Sciences